NCT04889495: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer |
|
|
| Not yet recruiting | N/A | 400 | NA | Zirabev | Pfizer | Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 05/25 | 05/25 | | |